Enducal, Nida P.
HRN: 15-51-18 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/24/2022
CEFTAZIDIME 1GM (VIAL)
05/24/2022
05/31/2022
IV
1 Gram
Q8hrs
CAP; Presumptive PTB, Relapse
Waiting Final Action
Indication: Empiric Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes